A Prospective Phase II Study of Safety and Efficacy of Sorafenib Followed by ⁹⁰Y Glass Microspheres for Patients with Advanced or Metastatic Hepatocellular Carcinoma.

ABSTRACT:

Purpose

The most common cause of death in advanced/metastatic hepatocellular carcinoma (HCC) is liver failure due to tumor progression. While retrospective studies and meta-analyses of systemic therapy combined with liver-directed therapy have been performed, prospective studies of safety/efficacy of antiangiogenesis followed by intra-arterial therapies are lacking. We tested our hypothesis that sorafenib followed by yttrium 90 glass microspheres (⁹⁰Y GMs) is safe and that survival outcomes may improve by controlling hepatic tumors.

Methods

We enrolled 38 Child-Pugh A patients with advanced/metastatic HCC. In sum, 34 received sorafenib, followed after 4 weeks by ⁹⁰Y GMs. Analysis of safety and survival outcomes was performed to assess adverse events, me

SUBMITTER: Kaseb AO 

PROVIDER: S-EPMC8437411 | biostudies-literature | 2021

REPOSITORIES: biostudies-literature